Global Recombinant DNA Technology Market, by Product Type (Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy, and Gene Editing), by Application (Therapeutics, Agriculture, and Research), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 106.8 Billion in 2017 and is projected to exhibit a CAGR of 7.9% over the forecast period (2017 – 2025).
The recombinant DNA technology market is expected to gain significant traction, owing to the availability of a broad range of approved recombinant therapeutics, presence of novel rDNA based gene editing systems in the clinical trials, and higher number of CAR-T gene therapies in the developmental pipeline over the forecast period.
Increasing number of approvals from regulatory agencies for novel recombinant DNA based therapies to augment market growth
Recombinant DNA technology has multidisciplinary applications which deals with important aspects of life such as health improvement and food enrichment. Various novel recombinant products have been approved by the regulatory agencies favoring the rapid launch and availability of innovative therapeutics, thus bolstering the market growth. Recombinant DNA technology has played a vital role in improving health conditions for patients diagnosed with asthma, hemophilia, and cancer by developing new vaccines and pharmaceuticals. For instance, in 2015, the FDA approved Nucala (mepolizumab) made by GlaxoSmithKline Plc., a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells, to treat severe asthma, thus providing a therapeutic boon to address the rising patient pool.
According to the Centers for Disease Control and Prevention (CDC), 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations annually. Also, in 2016, CSL Behring received FDA approval for Idelvion, Coagulation Factor IX, albumin fusion protein produced by recombinant DNA technology, for use in children and adults with Hemophilia B. Moreover, the application of this technology in the field of gene therapy has advanced the therapeutic potential targeting the life threatening diseases. For instance, in 2017, Novartis AG received FDA approval for Kymriah (tisagenlecleucel), the first chimeric antigen receptor T cell (CAR-T) therapy, indicated for the treatment of acute lymphoblastic leukemia (ALL).
Browse 38 Market Data Tables and 26 Figures spread through 183 Pages and in-depth TOC on “Recombinant DNA Technology Market”- Global Forecast to 2025, by Product Type (Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy and Gene Editing), by Application (Therapeutics, Agriculture and Research), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the recombinant DNA technology market, click the link here:
Manufacturers and biotechnology institutes are undertaking research activities to explore and launch novel therapies based on the gene editing systems to treat sickle cell anemia and cancer, thus favoring the market growth. For instance, in 2016, the Columbia University Medical Center (CUMC) and University of Iowa scientists used CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide. In January 2018, researchers from University of Pennsylvania were involved in CRISPR based therapy on cancer and have received approval to conduct the first CRISPR trial treating human patients in the U.S. from the National Institutes of Health and the FDA to treat melanoma, sarcoma, and multiple myeloma.
Key Takeaways of the Recombinant DNA Technology Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.